6%) 0.5 Gall bladder polyp (HGD) n = 1 (3%) n = 0 0.4 Conclusion: A MRI/MRCP surveillance strategy for hepato-biliary cancer in PSC patients was not associated with improved detection of malignancy. VI NGUYEN,1 PK TAN,1 A GREENUP,1 A GLASS,1 S DAVISON,1 U CHATTERJEE,2 S HOLDAWAY,3 D SAMARASINGHE,3 SA LOCARNINI,4 MT LEVY1,2 1Department of Gastroenterology & Hepatology, Liverpool Hospital, New South Wales, Australia, 2University of New South Wales, New South Wales, Australia., 3Department of Gastroenterology

& Hepatology, Westmead Hospital, New South Wales, Australia, 4Victorian Infectious Diseases Reference Laboratory, Melbourne, Victoria, Australia. Background and aims: Information on the nature of post-partum flares in the setting of hepatitis B virus (HBV) infection is limited. Antepartum antiviral therapy is administered to prevent perinatal transmission from mothers with a high viral load, but there PLX4032 is a concern this might exacerbate post-partum flare. The aim of this study was to examine

whether extending antiviral therapy beyond birth influences the post-partum course. Methods: Pregnant women with HBV and a high baseline viral load (≥log 7 IU/ml) were prospectively recruited Maraviroc cost from multiple tertiary centres in Sydney, Australia from November 2007 till 2013. From 2007 till 2009 lamivudine was given in the last trimester (from 32 weeks gestation) and continued for an average of 2 weeks post-partum. Concerns about the potency and resistance of lamivudine led to a change to tenofovir in 2010. From 2011 post partum duration was extended to 12 weeks in an effort to abrogate flares. Consenting women who declined treatment were included in a natural history arm. Virological, clinical and biochemical parameters were followed. Outcomes by post-partum treatment duration were assessed in three groups: Group1 = treatment ≤4 weeks, Group2 = treatment > 4 weeks, and Group3 = natural history arm. Results: Data from 91 pregnancies in 83 women where at least two ALT measurements post-partum

were available were included for analysis. Median age was 29 years, baseline viral load was log 7.85 IU/ml and ALT 25 U/ml (range 6–521 U/ml). learn more Median follow-up was 48 weeks post-partum. Median treatment duration post-partum was 2 weeks for Group 1 (n = 42), and 12 weeks for Group 2 (n = 35). 14 women had no treatment. Flare rates; Group 1 = 21/42 (50%), Group 2 = 14/35 (40%), and Group 3 = 4/14 (29%) were not significantly different across the treatment groups [p = 0.34]. The median time of flare onset was similar: 8/10/9 weeks for groups 1/2/3 respectively [p = 0.49]. Treatment duration also had no impact on flare severity, however did appear to influence the time to flare resolution [F(2,21) = 5.86, p = 0.01]. Post-hoc comparisons revealed the mean duration of flares in Group 2 (M = 16.5 weeks, SD = 10.07) were significantly longer than those observed in Group 1 (M = 7 weeks, SD = 4.04) and Group 3 (M = 6.5 weeks, SD = 3.00).